Summary

• No dose adjustment for INVEGA TRINZA is needed based on body mass index (BMI). However, slower absorption was observed in overweight and obese patients.¹
  • Higher BMI may delay achieving therapeutic plasma concentrations of paliperidone if patients are not treated with paliperidone palmitate 1-month (PP1M) for at least 4 months before transitioning to INVEGA TRINZA. Once steady state was achieved with INVEGA TRINZA the trough concentrations were similar among normal, overweight, and obese patients.¹
• A phase 3 study demonstrated that after multiple INVEGA TRINZA injections, paliperidone dose-normalized C_max and AUC are independent of BMI. This data is consistent with the pharmacokinetic analysis results that BMI only influences the volume of distribution for INVEGA TRINZA.¹
• The recommended needle size for the administration of INVEGA TRINZA into the deltoid muscle is determined by the patient’s weight.¹
  • For those <90 kg, the 1-inch, 22 gauge thin wall needle is recommended.
  • For those ≥90 kg, the 1½-inch, 22 gauge thin wall needle is recommended.
• The recommended needle size for administration of INVEGA TRINZA into the gluteal muscle is the 1½-inch, 22 gauge thin wall needle regardless of patient weight, to avoid administration into the adipose layer.¹

LITERATURE SEARCH

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources including internal/external databases) pertaining to this topic was conducted on 02 April 2024.